GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation

GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

2020 ARVO Annual Meeting, Baltimore (MD), US – cancelled

2020 AAN Annual Meeting, Toronto, Canada – canceled due to COVID-19

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

46th NANOS Annual Meeting, Amelia Island, Florida, US